Diagnostic devices for performing diagnostic tests are provided, as well as methods that utilize the diagnostic devices, methods for manufacturing the diagnostic devices, and test kits for performing the diagnostic tests. The diagnostic devices include a sample chamber with an opening for receiving a sample; a fluid chamber containing a fluid; and a test and readout chamber containing a lateral-flow assay (LFA) strip. The fluid chamber and/or the test and readout chamber is/are burstable and is/are configured to be in fluid connection with the sample chamber upon bursting. The fluid chamber may be flexible and configured to burst at a seal separating the sample chamber from the fluid chamber. The seal maybe configured to break when a bursting force is applied to the fluid chamber.

This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.

Provided are an antibody or antigen-binding fragment thereof that specifically binds to hepatitis B virus surface antigen (HBsAg), a pharmaceutical composition containing the antibody or antigen-binding fragment, and use thereof. Further provided are a nucleic acid molecule encoding the antibody, a vector and a host cell containing the nucleic acid molecule, and a method for preparing the antibody.

Peptide epitopes identified in subjects infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methods of use thereof for diagnosing, determining prognosis, and treating Coronavirus Disease 2019 (COVID-19), and developing prophylactic or therapeutic vaccines against SARS-CoV-2.

The present disclosure relates to a novel murine parvovirus, sequences encoded thereby, and applications therefor. In one embodiment the disclosure provides a method for detecting the presence of a parvovirus in a sample, comprising detecting one or more nucleic acids or polypeptides derived from the parvovirus, or antibodies against the parvovirus, in the sample. Also provided are vectors and host cells comprising sequences encoded by the parvovirus and related sequences. Also provided are animal models of kidney disease associated with infection by the parvovirus.

A protein microarray, a use thereof, and a detection method thereof are provided. The protein microarray includes a carrier with a protein array block on a surface thereof and at least two kinds of proteins immobilized on the protein array block. The at least two kinds of proteins include an extracellular region or a receptor binding region of the spike protein of a virus or a variant thereof. The protein microarray can detect the protective efficacy of vaccines, antibody drugs, or small molecule drugs against viral infection, or detect the immune response of an individual after vaccination or infection with a variant strain of the virus. The detection method of protein microarray includes the steps of adding the serum, a first fluorescent labeled human angiotensin converting enzyme 2, and a second fluorescent labeled anti-human immunoglobulin antibody to the protein microarray array and detecting optical signals.

A method of detecting SARS-CoV-2 virus antigen present in oropharyngeal lavage comprises: abstaining from food and drink for a first period of time before collecting the oropharyngeal lavage; pouring a non-alcoholic mouth rinse into the oral cavity, and swishing and gargling the non-alcoholic mouth rinse for a second period of time; inserting an absorbent end of a fluid collector comprising an absorbent material into the oral cavity to collect the oropharyngeal lavage from the oral cavity; removing the absorbent end of the fluid collector from the oral cavity; inserting the fluid collector into the sample receiving member of an analyte testing device for testing a fluid sample, with the absorbent end facing downward; and after a third period of time, reading a first indicator on a first test strip in the device to determine whether SARS-CoV-2 virus antigen is detected in the oropharyngeal lavage.

A biosensor capable of detecting both the SARS-CoV-2 S1 spike protein antigen and the SARS-CoV-2 spike protein IgG antibody is disclosed. In various embodiments, the biosensor is configured with an array of solution-gated nanoribbon FETs, wherein each nanoribbon comprises indium oxide (In.sub.2O.sub.3). In various aspects, the biosensor is fabricated using a scalable and cost-efficient lithography-free process comprising shadow masking.

This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.

Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.